Connect with us

Business

Reduce price of COVID-19 drug FabiFlu by 27%,New MRP approx ₹ 75/tablet.

Published

on

Drug firm Glenmark Pharmaceuticals on July 13 said it has cut price of its antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19, by 27 percent to Rs 75 per tablet.

Glenmark Pharmaceuticals had launched FabiFlu last month at a price of Rs 103 per tablet.

In a regulatory filing Glenmark announced a price reduction of 27 percent for FabiFlu. The new maximum retail price (MRP) is Rs 75 per tab, it said.

“The price reduction has been made possible through benefits gained from higher yields and better scale, as both the active pharmaceutical ingredient (API) and formulations are made at Glenmark’s facilities in India, the benefits of which are being passed on to patients in the country,” the filing said.

“Our internal research shows us that we launched FabiFlu in India at the lowest market cost as compared to the cost of Favipiravir in other countries where it is approved. And now we hope that this further price reduction will make it even more accessible for patients across the country,” Glenmark Pharmaceuticals Senior Vice President and Head – India business Alok Malik said.

Further, the company has commenced a post marketing surveillance (PMS) study on FabiFlu to closely monitor the efficacy and safety of the drug in 1,000 patients that are prescribed with the oral antiviral, as part of an open label, multi center, single arm study, the filing added.

“We expect this post marketing surveillance study to shed more light on the drug’s clinical effectiveness and safety in a large cohort of patients prescribed FabiFlu,” Malik added.

On June 20, Glenmark announced that it received manufacturing and marketing approval from India’s drug regulator for FabiFlu, making it the first oral Favipiravir-approved medication in India for the treatment of mild to moderate COVID-19.

Glenmark has also completed the phase 3 clinical trial with Favipiravir (FabiFlu) in mild to moderate COVID-19 patients in India. The trial results will be available shortly, the company said.

Glenmark is also conducting another phase 3 clinical trial to evaluate the efficacy of two antivirals drugs Favipiravir and Umifenovir as a combination therapy in moderate hospitalised adult COVID-19 patients in India.

Business

At the age of 16, this boy started the clothing business, earned 9 crore rupees in just one year

Published

on

By

At the age of which most boys do not even think what they want to do in their life, at that age this boy has shown the work that most people can only dream of.

The name of this boy is Dillan Bhardwaj, who became a millionaire at the age of just 16.

He became a millionaire at the age of 16. He started designing clothes from the home garage which proved to be a hit. Due to this he became the owner of the clothing chain Ratchet in the same year and he earned around 9 crores in the first year.

Her clothing line dress has been worn by stars like Rihanna and Miley Cyrus. With this success, his lifestyle also changed. Today Dhillon lives in a 42-acre bungalow. His bungalow has a lot ranging from 5 living rooms to three kitchens, a tennis court, cinema, gym and 20 bedrooms.

Not only this, they have about 20 luxury cars. This includes everything from Rolls Royce to Ferrari, Lamborghini and BMW. Today Dhillon has shops in Long Eaton, Broadmarsh Center and Sheffield.

 

Continue Reading

Trending